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Background: Previous analyses of the listings of trastuzumab on the Australian Pharmaceutical Benefits Scheme
(PBS) and HPV vaccine on the National Immunisation Program (NIP) suggest a media influence on policy makers.
We examined the timing and content of Australian newspaper reports of medicines in relation to Pharmaceutical
Benefits Advisory Committee (PBAC) decisions.
Methods: We identified newspaper reports (2005-2008) of medicines recommended for PBS listing in 2006–2007,
analysing the content for mentions of the medicine, PBS and medicine costs to the patient and the government
and counting the numbers of articles published in the six months before, the month of, and the six months after
the relevant PBAC meeting. Case studies examined reporting for infliximab for Crohn’s Disease, pemetrexed for
mesothelioma, and ADHD (Attention Deficit Hyperactivity Disorder) medicines atomoxetine and methylphenidate.
Results: Of 79 eligible medicines, 62 had news reports. Most often reported were HPV vaccine (1230 stories),
trastuzumab (410), pemetrexed (83), botulinum toxin (71), lapatinib (65), methylphenidate (57), atomoxetine (54),
infliximab (49), rotavirus vaccine (45). Eighteen medicines had ≥20 news reports (total 2350 stories); nine of these
cost more than AU$10,000 per course or year of treatment. For these 18 medicines, 31% of stories appeared in the
six months prior to the PBAC meeting, 14% in the meeting month and 33% in the six months post-meeting. 38%
of the stories had ≥3 medicine mentions, 37% referred to the PBS, 24% to cost to the patient, and 9% cost to
Government.
There was active patient lobby group campaigning in support of listing of infliximab and pemetrexed; the stories
for ADHD were often more negative, referring to the dangers of the medicines and sometimes questioning
the appropriateness of treatment and public subsidy. There was little discussion of the PBAC’s evidence-based
decision-making processes.
Conclusions: While there was no general trend to increased news reporting associated with PBAC meetings, some
drugs did attract media attention. With more new and expensive drugs, decisions on public funding will become
increasingly difficult. The media have an important role in enhancing public understanding of the issues around
resource allocation. Specialist journalists, guidelines and checklists may help reporting.
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The news media are an important source of information
on health and medical advances for consumers. How-
ever, the quality of media coverage is variable, with con-
cerns about exaggerated claims of benefits, inadequate
coverage of harms, a lack of information on treatment
costs, and limited use of independent expert opinion to
interpret the balance of benefits and harms for con-
sumers [1-4]. Reporting about medicines varies in its
focus and impacts. Newspaper stories around the time
of marketing of a new medicine can increase public
awareness, [5] and may promote patient requests for the
product [6,7]. Business news reports relate to share
prices and projected profits for pharmaceutical compan-
ies; while adverse publicity on drug safety can have dra-
matic negative effects on market values [8,9].
Australia’s Pharmaceutical Benefits Scheme (PBS) is a
publicly funded insurance scheme aimed at providing
universal affordable access to prescription medicines
[10]. Approximately 80% of the prescription medicines
used in Australia are subsidised under the scheme [11].
The private prescription market for medicines not listed
on the PBS is estimated to be around 5% of total pre-
scriptions, the remainder funded by other Common-
wealth and State programs [12]. All patients contribute a
per prescription co-payment until reaching a threshold
after which a ‘safety net’ comes into effect; the safety net
serves to protect individuals and families with high
medication needs [13]. The Pharmaceutical Benefits
Advisory Committee (PBAC) is an independent statutory
body that makes recommendations to the Minister for
Health on the drugs and medicinal preparations to be
subsidised on the PBS or included in the National Im-
munisation Program (NIP). In doing so, the PBAC con-
siders the safety, efficacy and cost-effectiveness of the
proposed medicine [10]. Where the PBAC has rejected
the application, the sponsor may re-submit any number
of times, generally with revised clinical data or clinical
claims, changed utilisation estimates or alternate pri-
cing proposals.
Two recent Australian case studies (trastuzumab for
breast cancer, Herceptin®) and HPV cervical cancer vac-
cine, Gardasil®) suggest a media role in increasing political
pressure to influence decision-makers [14,15]. The pres-
sure was directed at the Federal Government to commit
substantial public money to subsidise an otherwise expen-
sive and mostly unaffordable drug (trastuzumab), and to
include the new HPV vaccine in the NIP.
After three rejections by the PBAC for listing for late
stage cancer during the 1990s, intensive lobbying before
the 2001 Federal election resulted in public subsidisation
of trastuzumab in a special program independent of
the PBS [14]. In 2006, a “crescendo of media demands”
for trastuzumab to be available for early stage cancerpreceded PBS listing. Reviewing 43 television news and
current affairs stories regarding trastuzumab, MacKenzie
et al. concluded “the dominant discourse across the news
coverage was that Herceptin was a ‘wonder drug’ made
unaffordable to the majority of women with HER2 breast
cancer by government indifference, labyrinthine bureau-
cracy and unacceptable, cruel financial parsimony” [14].
The initial decision to reject funding of the HPV vaccine
led to over 300 newspaper articles and calls by con-
sumers, health professionals and politicians to intervene
in the decision-making process [15].
Given these and other examples of media influence on
the formulation of health policy, [5,16] we examined the
numbers of stories published in Australian newspapers
on medicines seeking public subsidy and their timing in
relation to PBAC decision-making. We expected there
would be increased levels of media reporting in the
months leading up to PBAC meetings, these would be
highest in the month of the PBAC meeting, and there
would be limited media coverage after the positive rec-
ommendation to list the medicine on the PBS. In
addition, we sought to characterise the reports in terms
of mentions of the PBAC and its decision-making, drug
costs and budgetary impact of the listing decision.
Methods
We identified medicines considered by the PBAC for
PBS listing in 2006 and 2007 [17]. We searched the
ANZ Proquest Newsstand database [18] from 1 July
2005 to 30 June 2008 to find Australian newspaper arti-
cles pertaining to these medicines. At the time of this
study, the database included more than 40 newspapers,
covering the major daily and weekend newspapers of all
capital cities and major regional centres [18]. Using gen-
eric and trade names, we searched the database for men-
tions of the medicine in the headline or text of reports
and retrieved the full text of each identified article.
We counted the numbers of stories appearing in the
six months before, the month of the meeting and six
months after the PBAC meeting. Each story was coded
for the number of times the medicine name was
reported (1, 2 or ≥3 mentions), assuming that more
mentions would reflect a greater medicine focus in the
newspaper report. Stories identified in the three year
time window (2005–2008) were coded for reference to
the PBS (either use of the term PBS or reference to Gov-
ernment subsidy or medicine subsidisation), and medi-
cine costs (either patient costs if it was not subsidised,
or Government costs for providing subsidised access).
Each story was coded by two raters, with differences
in categorisations resolved by consensus or by adjudica-
tion using a third reviewer where agreement could not
be reached. Descriptive statistics are used to summarise
the data.
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ports, three case studies where there were larger num-
bers of newspaper articles published around the time of
the PBAC recommendation are used to illustrate the
content and tenor of some reporting.
Results
Medicines recommended for PBS listing
Seventy-nine medicines receiving a positive PBAC rec-
ommendation for listing in 2006 (42 medicines) and
2007 (37 medicines) were identified. Ten of these medi-
cines had more than one application to the PBAC for
use in different clinical conditions. Eight medicines
were the subject of 50 or more news reports in the
eligible time frame (2005–2008), 10 had 20–49 reports,
18 had 10–19 reports, 26 had <10 reports and 17 medi-
cines were not mentioned in any news report (see
Appendix I). In total, 2664 stories relating to 62 medi-
cines were identified.
Medicines receiving greatest newspaper coverage were
HPV vaccine (1230 stories), trastuzumab (410), pemetrexed
(83), botulinum toxin (71), lapatinib (65), methylphenidate
(57), atomoxetine (54), Tdap (tetanus, diphtheria and acel-
lular pertussis) vaccine (53), infliximab (49), and rotavirus
vaccine (45). The 18 medicines with 20 or more newspaper
reports were mentioned in 2350 stories (88% of eligible ar-
ticles). Nine of these 18 medicines cost more than AU
$10,000 per course or year of treatment (see Table 1).
Of the 18 highly reported medicines, six (33%) were
treatments for cancer or other malignancies (docetaxel,
imatinib, lapatinib, paclitaxel, pemetrexed, trastuzumab),
three were vaccines (HPV, rotavirus, Tdap), two were used
to manage Attention Deficit Hyperactivity Disorder
(ADHD; methylphenidate, atomoxetine), and five were for
severe, often debilitating chronic conditions (infliximab
for Crohn’s disease and psoriatic arthritis, fentanyl for
severe chronic pain, natalizumab for multiple sclerosis,
ranibizumab for macular degeneration, sildenafil for pul-
monary hypertension). Botulinum toxin reports in the
eligible time period related almost exclusively to its cos-
metic ‘Botox’ uses rather than its PBS listing for spasticity.
Five of these 18 medicines (infliximab, docetaxel, fentanyl,
methylphenidate, varenicline) were the subject of more
than one PBS recommendation during the eligible study
period increasing the opportunities for news reports for
these drugs.
Timing of these 2350 news reports in relation to
PBAC meetings is shown in Table 1. Across these 18
medicines, 31% of the reports appeared in the 6 months
prior to the PBAC meeting, 14% in the month of the
meeting and 33% in the 6 months after the positive
PBAC recommendation. For this same subset of 18 med-
icines, there were ≥3 mentions of the medicine in 38%
of the stories, reference to the PBS in 37%, personal costto the patient of the medicine in 24%, and overall cost to
Government in 9% (Table 2). Personal cost in the absence
of subsidy was mentioned most often for oncology medi-
cines (docetaxel, lapatinib, pemetrexed, trastuzumab, 51%
of stories for these medicines) and the monoclonal anti-
bodies (infliximab, natalizumab, ranibizumab, trastuzumab,
52% of stories). Government subsidy (67.7%) and personal
cost of the medicine (48.3%) were mentioned more fre-
quently in the stories for the nine medicines costing more
than AU$10,000 per course or year of treatment than
overall. However, other high-cost medicines including
bortezomib (7 stories) and dasatinib (1 story) received min-
imal media attention.
While there was no general trend to increased news
reporting associated with PBAC meetings, some drugs did
attract substantial media attention. We conducted add-
itional qualitative analyses of reports for two medicines
(infliximab for the treatment of Crohn’s disease and
pemetrexed for mesothelioma) and one class of medicines
(ADHD medicines, atomoxetine and methylphenidate).Case study – infliximab (5th application for PBAC listing)
There was a peak of reports in the month prior to the
positive PBAC recommendation for subsidised use of
infliximab in adult Crohn’s disease. In these articles, the
case for infliximab was sometimes personalised with iden-
tifiable victims No joy for Sharron after $3000 magic pill
rejected, [19] Jill Knox may have to remortgage her home,
[20] Nicole O’Malley’s years of agony [21]. Patients were
described as let down by the health system [20] and suffer-
ing needlessly [22]. Doctors were forced to offer second-best
treatment to desperate people who deserve better [23].
There was active lobbying by the Australian Crohn’s
and Colitis Association [24] specialist physicians and pa-
tients [25] (www.infliximab.org) and a petition of 25,000
signatures was delivered to Health Minister Tony Abbott
demanding a listing of the drug [26].
One newspaper view before listing was that is unaccept-
able. Actually it is un-Australian. That’s not how we do
things… a public campaign is the only chance [27]. After
the positive recommendation, newspaper reports noted it
was long overdue, [28] there was hip pocket relief, [29] and
that it was close to winning a seven year battle [30]. The
decision was described as a backflip following extensive
lobbying, [30] commenting they’ve obviously listened to
the public [31].Case study – pemetrexed (4th application for listing)
The story of pemetrexed (marketed as Alimta® in Australia)
involved a very public face of a disease resulting from
exposure to asbestos. Bernie Banton led the fight on behalf
of workers and unions against James Hardie Industries for
the establishment of an adequate compensation fund for
Table 1 Medicines with >20 newspaper articles (July 2005-June 2008)
Generic name, brand name
(Indication for PBS listing)
No. of
articles
Number of articles located
Articles in 6 months prior Articles in PBAC meeting month Articles 6 months post
HPV vaccine 1230 484 215 409
(NIP)
Trastuzumab † 410 113 32 104
(Breast cancer)
Pemetrexed † 83 20 39 16
(Mesothelioma)
Botulinum toxin 71 11 1 26
(Spasticity)
Lapatinib † 65 14 4 21
(Breast cancer)
Methylphenidate 57 12 3 27
(ADHD)
Atomoxetine 54 6 4 25
(ADHD)
Tdap vaccine 53 9 4 20
(NIP)
Infliximab † 49 12 3 32
(Crohn disease, psoriatic arthritis)
Rotavirus vaccine 45 13 5 16
(NIP)
Varenicline 39 1 1 24
(Smoking cessation)
Docetaxel † 36 3 4 17
(Breast cancer, prostate cancer)
Fentanyl 30 6 4 8
(Severe pain)
Sildenafil † 28 5 0 0
(Pulmonary hypertension)
Paclitaxel 27 3 3 11
(Breast cancer)
Imatinib † 26 2 0 6
(Acute lymphoblastic leukaemia)
Ranibizumab † 26 4 2 9
(Macular degeneration)
Natalizumab † 21 2 0
(Multiple sclerosis)
Total 2350 720 324 783
Abbreviations: NIP, National immunisation program; ADHD, Attention-deficient hyperactivity disorder; HPV, Human papillomavirus; Tdap, Tetanus, diphtheria,
acellular pertussis.
† Cost more than AUD$10,000 per year or course of treatment.
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the disease.
Before the PBAC recommendation for listing (November
2007), patients were described as innocent victims: my onlycrime was to go to work [32], contracting a deadly disease
through no fault of their own [33]. There were women af-
fected many of whom probably did nothing more than wash
their husbands’ asbestos coated overalls [34].
Table 2 Content of newspaper articles
Medicine or vaccine
(total number of articles)
% of articles mentioning #
3+ drug mentions Govt subsidy Personal cost Govt cost
HPV vaccine (n = 1230) 43 20 13 10
Trastuzumab † (n = 410) 41 67 51 10
Pemetrexed † (n = 83) 20 99 45 7
Botulinum toxin (n = 71) 8 4 17 1
Lapatinib † (n = 65) 32 55 42 2
Methylphenidate (n = 57) 70 47 26 18
Atomoxetine (n = 54) 30 67 15 26
Tdap vaccine (n = 53) 9 13 0 0
Infliximab † (n = 49) 27 82 45 2
Rotavirus vaccine (n = 45) 13 73 24 20
Varenicline (n = 39) 51 51 5 3
Docetaxel † (n = 36) 31 97 78 19
Fentanyl (n = 30) 13 7 0 3
Sildenafil † (n = 28) 11 0 0 0
Paclitaxel † (n = 27) 4 7 0 4
Imatinib † (n = 26) 54 19 12 0
Ranibizumab † (n = 26) 42 62 69 19
Natalizumab † (n = 21) 38 76 62 19
Total 38 37 24 9
† Cost more than AUD$10,000 per year or course of treatment.
# Totals do not sum to 100% as an article may be included in more than one category.
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greatest injustices in Australian history that people who
smoked voluntarily can get this drug on the PBS
[subsidised for some lung cancers] but people with meso-
thelioma can’t [35]. A sense of entitlement was reflected
in a comparison with other subsidised medicines why
won’t the Government bankroll an effective cancer-
fighting drug yet it spends millions of dollars a year pro-
viding methadone to more than 30,000 heroin addicts,
[36] I paid tax all my working life…,[32] and it is not too
much to ask that a Government …shows some common-
sense compassion instead of callous, cold-blooded ration-
alism [37]. The Asbestos Disease Foundation noted it
was appalling that we can spend so much money going
to war and all sorts of other things but when it comes to
the medicine and treatment of these tax-paying Austra-
lian people we just can find the sense and logic to pro-
vide the medicine as required [38].
When politicians were challenged about the situation,
responses referred to an independent, expert committee
[PBAC], [39] and noting the need for companies to re-
spect the processes for drug approvals for PBS listing [39].
There was active lobbying of PBAC and parliamentar-
ians. The then Health Minister dismissed the delivery of
a 17,000 signature petition from Bernie Banton as a pub-
licity stunt, earning the ire of the media, and provokingthe response that it was an unacceptable attack on a
great Australian [40]. It resulted in prolonged media
coverage around listing of the drug.
The positive decision to list on the PBS was reported
as Bernie wins battle [41]. We found only one article
that provided any detail on the PBAC decision: [the
manufacturer] dropped the price [by 10%], changed the
way it was packaged to reduce waste and cost and pro-
vided more data about how it improved patients’ quality
of life [42].
Bernie Banton commented on possible political inter-
ference in the final decision: Tony Abbott [Health Minis-
ter] assured me there was no political interference in this
decision but I would not have liked to have been him if
the decision had gone the other way [43].
The reporting of the successful listing of pemetrexed
was overshadowed by the death of Bernie Banton with
tributes and the offer of a State funeral.
Case study – atomoxetine and methylphenidate for ADHD
In contrast to the apparent support for listing of infliximab
and pemetrexed in some newspaper reports, the discourse
for the ADHD medicines often related to the dangers of
the drug: deadly side to ADHD treatment, [44] when the
costs of a well behaved child could be hallucinations or
death [45]. Sometimes, the language of drugs of addiction
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cocaine; [47,48] … a further 58 four-year-olds and 13
three-year-olds are also wandering the state like space ca-
dets; [47] Australia’s dependency on ADHD drugs; [46] and
New front opens on ADHD war [49].
There was also commentary implying the apparently
reckless use of these drugs in very young children when
perhaps better parenting and discipline were more ap-
propriate: giving quick and careless prescribers the op-
portunity to prescribe a drug, [50] Prescribe discipline
not drugs for children, [51] quick fix drugs to solve be-
havioural problems, [45] Has a normal childhood be-
come a disorder? [52]. There was particular ire at their
use in pre-school age children: Drugs for Toddlers? You
must be kidding, [47] … you just don’t mess with the
heads of babies, [47] and using mind-altering drugs…
while still in nappies. [47]
The debate was fuelled by comments from politicians
and members of the judiciary expressing their concerns
about use of these drugs [53] that had created a gener-
ation of Ritalin kids who were committing violent crimes
and coming before the courts [48]. It was noted that the
Prime Minister was…very worried about the rate of pre-
scribing of ADHD drugs; [54] ….left open the possibility
of a national enquiry into the ADHD epidemic [48].
In the view of one medical specialist …I think the
numbers [of children prescribed the drugs] are not bad
actually… we’re not doing such a bad job [47] (the fig-
ures follow the State Government’s ADHD review which
found there was no overprescribing of drugs). So diffi-
cult was the environment that a specialist involved in
developing guidelines for the use of these drugs de-
scribed the task as a “contentious project”, noting “…
there’s a high amount of emotional content from the
media feeding into the politicians and presumably other
dark forces are working in the background and the whole
process has been put on hold” [55].
Readers of some newspapers were invited to contrib-
ute their opinions on a complex social issue in simple
yes/no polls: Does the issue concern you? [56] Should
taxpayers be forced to subsidise ADHD drugs? [54]
Should there be a Ritalin age limit? [57].
Discussion and conclusion
Most of the medicines considered by the PBAC in 2006–
2007 generated little or no newspaper coverage. Medicines
that were the focus of media reports included biological
agents (monoclonal antibody therapies) and treatments
for high profile diseases such as breast cancer, prostate
cancer, ADHD, leukaemia and multiple sclerosis. Men-
tions of government subsidy and cost to the patient were
more frequent for high-cost medicines (e.g. pemetrexed).
We found no evidence of increased intensity of newspaper
reporting close to the time of PBAC meetings.While overall, most newspaper stories were not published
in close proximity to the PBAC consideration for listing
there was heightened media activity for a number of spe-
cific drugs. Whether the newspapers are actively mounting
and promoting campaigns or are the agency for the cam-
paigns of other interest groups is less clear. For both
infliximab and pemetrexed, there were well-organised pa-
tient groups and disease associations, with petitions deliv-
ered to Government. In addition to reporting, at least one
media outlet suggested a public campaign as the only
chance; [27] and the subsequent successful listing was at-
tributed in part to listening to the public view. In some
cases the advocacy is clearer with one newspaper (Sunday
Herald Sun) congratulating itself on the success of its media
campaign to have treatment with trastuzumab subsidised
by the Government; [58] Breast Cancer Network Australia
was confident their pressure had “won the day” [59].
In a study of the representation of prescription medi-
cines in UK newspapers, Prosser concluded that the
media often constructs a discrete, contradictory, and fre-
quently oversimplified set of characterizations about
medicines - the contrast of marvellous medicines and
dangerous drugs [60]. Our selected case studies illustrate
the potential for this, with super effective, wonder drugs
like pemetrexed, infliximab, trastuzumab (marvellous
medicines) and the potential dangers of medicines to
treat ADHD. In the case of ADHD, even the diagnostic
criteria are contentious, [61] and the use of the termin-
ology of drugs of addiction and the language of battle
[60] (ADHD war) will tend to reinforce negative public
opinion. Health care professionals seeking to mount a
public campaign against perceived over-prescription of
these medicines will have also contributed to the nega-
tive reporting of these medicines [62]. The effect of
the media spotlight and the emotional content of the
discourse was sufficient to interfere with the work of
clinical experts trying to develop guidelines for use of
these drugs.
While the costs of medicines to both patients and the
Government featured in many of the stories, there were
few challenges to pharmaceutical companies to justify
the prices being asked for some of these medicines.
There were few references to the decision-making pro-
cesses used by the PBAC, with its emphasis on evidence
of benefit and formal assessment of cost-effectiveness
[10]. For pemetrexed, there was little discussion of the
potential cost implications of the expected growth in pa-
tient numbers of 600 per year to 18,000 cases by 2020
[41] or the projected gain in life-expectancy (proven to
offer two or three extra months of life) [63]. Interest-
ingly, there were references to the comparatively cheaper
ADHD medicines as costly tablets, [55] generating a bill
of almost $10 million per year that taxpayers were
forced to pay [46].
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was little recognition that the formal and independent
processes for the listing of drugs on the PBS had served
the Australian taxpayer well. The system is acclaimed
internationally and is generally believed to provide a
consistent and defensible framework for decision-
making delivering prices for new medicines lower than
most other countries. Among the media reports about
failure to fund the HPV vaccine and the pleas to the
Health Minister to circumvent the PBAC’s advice in re-
lation to the HPV vaccine, [64] few reports acknowl-
edged that vaccine listing on the NIP was achieved with
a substantial reduction in price from the manufacturer
[65]. An offer of a price reduction, repackaging to reduce
waste and more clinical data led to the final approval of
pemetrexed [42]. Intensive lobbying lead to the 2001 de-
cision to fund trastuzumab in a program separate to the
PBS; this mechanism to provide medicine access has
subsequently been described as “a mistake best not re-
peated” [59]. Applying different decision-making criteria
for specific diseases creates difficult precedents for both
government and the PBAC.
The case studies for infliximab and pemetrexed illus-
trate the use of identifiable victims to put a human face
on the disease and its consequences. Apart from en-
gaging reader attention, it also invokes the “rule of res-
cue”, i.e. the imperative people feel to rescue identifiable
individuals facing avoidable death, [66] and can increase
the likelihood of achieving the objective of gaining ac-
cess to expensive medicines [14].
Our study was limited to newspaper reports of medi-
cines drawn from a single news database, ANZ Proquest
Newsstand. While the repository does not include all
newspapers available in Australia and does not include
online and television news stories, the scope and size of
the readership of the included newspapers means that
the discourse observed in these articles is likely to be re-
flective of the information and views offered to the Aus-
tralian public. There was often syndication of stories to
other news outlets, or use in more than one edition of a
newspaper; we counted these as separate stories as an
editorial decision had been made to reproduce the story
and the readership was likely to be different. There were
few useful classification frameworks available to guide
our analysis of article content; our experience was that a
numerical count of drug mentions was not always a
good guide to article focus and content.
The results of this study suggest that mostly the PBAC
can apply its rigorous evidence-based assessments away
from the public gaze, however there are some decisions
that have to be taken in a politically and emotionally
charged environment. The media have a legitimate right
to report and to give voice to the range of viewpoints.
Some diseases lend themselves to more sympatheticattention than others (breast cancer and mesothelioma
compared to bowel cancer; [67,68]) however media
prominence is a poor basis for decision-making. These
funding decisions will become increasingly difficult as
the manufacturers of new and expensive medicines seek
public subsidy of agents that offer sometimes small
clinical gains over existing therapies. In this environ-
ment, the media can play an important role in improv-
ing public understanding of the issues around resource
allocation. Guidelines from professional associations
such as the Australian Press Council, [69] use of
checklists for journalists on key elements to include in
their stories, [70,71] and dedicated specialist health
journalists [71] may all help in improving the quality
of health reporting.
Appendix I
List of all drugs included in the study by number of arti-
cles referring to the medicine:
≥50 articles: HPV vaccine, Trastuzumab, Pemetrexed,
Botulinum toxin, Lapatinib, Methylphenidate, Atomoxetine,
Tdap vaccine (Adacel).
≥20 to 49 articles: Infliximab, Rotavirus vaccine,
Varenicline, Docetaxel, Sildenafil, Paclitaxel, Imatinib,
Ranibizumab, Fentanyl, Natalizumab
≥10 to 19 articles: Imiquimod, Rituximab, Rosuvastatin,
Insulin glargine, Adalimumab, Levonorgestrel, Topiramate,
Risperidone, Cetuximab, Ezetimibe, Ezetimibe with Simva-
statin, Budesonide with Eformeterol, Cinacalcet, Fluticasone
with Salmeterol, Pioglitazone, Etanercept, Insulin detemir,
Letrozole
1 to 9 articles: Exemestane, Pimecrolimus, Risedronate,
Bortezomib, Quetiapine, Famciclovir, Zonisamide, Calcipotriol,
Paliperidone, Sevelamer, Ziprasidone, Anecortave, Darunavir,
Pegfilgrastim, Trandolapril with Verapamil, Abatacept,
Alendronate, Bicalutamide with Goserelin, Dasatinib,
Entecavir, Ibandronic acid, Macrogol, MMRV vaccine,
Rosiglitazone with Metformin, Strontium, Triptorelin
No articles: Alendronate with Vitamin D3, Amlodipine
with Atorvastatin, Aprepitant, Deferasirox, Epoprostenol,
Leflunomide, Moxonidine, Olmesartan with Hydrochlorothi-
azide, Posaconazole, Ramipril with Felodipine, Risedronate
with Calcium, Sitaxentan, Tacrolimus, Thyrotropin alfa-rch,
Tipranavir, Travoprost withTimolol, Vinorelbine
Abbreviations
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